Radium-223 dichloride
Treatment for Prostate Cancer
Typical Dosage: 55 kBq/kg IV every 4 weeks for 6 doses
Effectiveness
65%
Safety Score
25%
Clinical Trials
76
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
55 kBq/kg IV every 4 weeks for 6 doses
Time to Effect
Weeks (pain relief)
Treatment Duration
5 months (up to 6 injections)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80,000
Monitoring:$4,000
Side Effect Mgmt:$4,000
Total Annual:$88,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$226,381/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$251,429
Comparison vs Best Supportive Care
Cost Difference
+$88,000/year
More expensive
QALY Difference
+0.25 QALYs
Better outcomes
Dominance
No dominance
Radium-223 dichloride Outcomes
for Prostate Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+35%
Common Side Effects
Nausea
+35%
Diarrhea
+25%
Vomiting
+20%
Thrombocytopenia
+15%
Anemia
+12%
Bone pain flare
+8%
Sources:
Active Clinical Trials
1 active trial recruiting for Radium-223 dichloride in Prostate Cancer
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
NCT05133440ACTIVE NOT RECRUITINGPHASE2
12 participants
INTERVENTIONAL
Aurora, United States +6 more
Started: Nov 12, 2021
Completed Clinical Trials
18 completed trials for Radium-223 dichloride in Prostate Cancer
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
NCT01565746COMPLETEDPHASE1
19 participants
INTERVENTIONAL
Kashiwa, Japan +2 more
Started: Mar 1, 2012
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
NCT01618370COMPLETEDPHASE3
705 participants
INTERVENTIONAL
Bruges, Belgium +214 more
Started: Jul 22, 2012
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
NCT01934790COMPLETEDPHASE1, PHASE2
45 participants
INTERVENTIONAL
New Orleans, United States +15 more
Started: Dec 22, 2013
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
NCT01810770COMPLETEDPHASE3
243 participants
INTERVENTIONAL
Guangzhou, China +26 more
Started: Mar 26, 2013
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
NCT03062254COMPLETEDPHASE2
14 participants
INTERVENTIONAL
Montreal, Canada
Started: Mar 22, 2018
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
NCT02398526COMPLETED
363 participants
OBSERVATIONAL
Multiple Locations, Germany
Started: Mar 19, 2015
Treatment Satisfaction With Ra-223 in Japan
NCT03315260COMPLETED
85 participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Apr 11, 2019
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
NCT02023697COMPLETEDPHASE2
391 participants
INTERVENTIONAL
Scottsdale, United States +67 more
Started: Mar 10, 2014
Treatment Patterns in Metastatic Prostate Cancer
NCT02729103COMPLETED
565 participants
OBSERVATIONAL
Whippany, United States
Started: Oct 31, 2016
Japanese BAY88-8223 Monotherapy Phase II Study
NCT01929655COMPLETEDPHASE2
49 participants
INTERVENTIONAL
Kashiwa, Japan +15 more
Started: Sep 30, 2013
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
NCT03223597COMPLETED
300 participants
OBSERVATIONAL
Amersfoort, Netherlands +19 more
Started: Jan 17, 2015
The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.
NCT03368989COMPLETED
21 participants
OBSERVATIONAL
Houston, United States
Started: Feb 11, 2014
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
NCT02450812COMPLETED
86 participants
OBSERVATIONAL
Multiple Locations, Germany
Started: May 28, 2015
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
NCT02899104COMPLETED
200 participants
OBSERVATIONAL
Whippany, United States
Started: Jun 15, 2017
BAY88-8223, Dose Finding Study in Patients With HRPC
NCT00337155COMPLETEDPHASE2
122 participants
INTERVENTIONAL
Sutton, United Kingdom
Started: May 1, 2006
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety
NCT04681144COMPLETED
103 participants
OBSERVATIONAL
Multiple Locations, Colombia
Started: Apr 8, 2021
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
NCT00459654COMPLETEDPHASE2
64 participants
INTERVENTIONAL
Linköping, Sweden +2 more
Started: Feb 1, 2004
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
NCT02814669COMPLETEDPHASE1
45 participants
INTERVENTIONAL
Duarte, United States +16 more
Started: Sep 23, 2016
Showing 20 of 76 total trials